GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (NYSE:LLY) » Definitions » Cyclically Adjusted PB Ratio

Eli Lilly and Co (Eli Lilly and Co) Cyclically Adjusted PB Ratio : 59.11 (As of Apr. 27, 2024)


View and export this data going back to 1970. Start your Free Trial

What is Eli Lilly and Co Cyclically Adjusted PB Ratio?

As of today (2024-04-27), Eli Lilly and Co's current share price is $733.51. Eli Lilly and Co's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $12.41. Eli Lilly and Co's Cyclically Adjusted PB Ratio for today is 59.11.

The historical rank and industry rank for Eli Lilly and Co's Cyclically Adjusted PB Ratio or its related term are showing as below:

LLY' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 4.09   Med: 8.18   Max: 63.19
Current: 59.13

During the past years, Eli Lilly and Co's highest Cyclically Adjusted PB Ratio was 63.19. The lowest was 4.09. And the median was 8.18.

LLY's Cyclically Adjusted PB Ratio is ranked worse than
99.38% of 647 companies
in the Drug Manufacturers industry
Industry Median: 1.75 vs LLY: 59.13

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Eli Lilly and Co's adjusted book value per share data for the three months ended in Dec. 2023 was $11.346. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $12.41 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eli Lilly and Co Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Eli Lilly and Co's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Cyclically Adjusted PB Ratio Chart

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.17 13.64 22.03 28.80 46.99

Eli Lilly and Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.80 26.87 36.73 42.35 46.99

Competitive Comparison of Eli Lilly and Co's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Cyclically Adjusted PB Ratio falls into.



Eli Lilly and Co Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Eli Lilly and Co's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=733.51/12.41
=59.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Eli Lilly and Co's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=11.346/129.4194*129.4194
=11.346

Current CPI (Dec. 2023) = 129.4194.

Eli Lilly and Co Quarterly Data

Book Value per Share CPI Adj_Book
201403 16.381 99.695 21.265
201406 16.096 100.560 20.715
201409 15.869 100.428 20.450
201412 13.842 99.070 18.082
201503 13.444 99.621 17.465
201506 13.234 100.684 17.011
201509 13.737 100.392 17.709
201512 13.183 99.792 17.097
201603 13.598 100.470 17.516
201606 13.260 101.688 16.876
201609 14.121 101.861 17.941
201612 12.724 101.863 16.166
201703 12.716 102.862 15.999
201706 12.807 103.349 16.038
201709 13.523 104.136 16.806
201712 10.538 104.011 13.112
201803 13.295 105.290 16.342
201806 10.759 106.317 13.097
201809 12.251 106.507 14.887
201812 9.298 105.998 11.353
201903 2.555 107.251 3.083
201906 2.878 108.070 3.447
201909 3.523 108.329 4.209
201912 2.723 108.420 3.250
202003 3.217 108.902 3.823
202006 4.279 108.767 5.091
202009 5.046 109.815 5.947
202012 5.898 109.897 6.946
202103 7.190 111.754 8.327
202106 6.737 114.631 7.606
202109 8.109 115.734 9.068
202112 9.416 117.630 10.360
202203 9.816 121.301 10.473
202206 8.993 125.017 9.310
202209 10.598 125.227 10.953
202212 11.208 125.222 11.584
202303 11.788 127.348 11.980
202306 11.655 128.729 11.718
202309 11.820 129.860 11.780
202312 11.346 129.419 11.346

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eli Lilly and Co  (NYSE:LLY) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Eli Lilly and Co Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co (Eli Lilly and Co) Business Description

Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Executives
Lilly Endowment Inc 10 percent owner 2801 NORTH MERIDIAN ST, INDIANAPOLIS IN 46208
Donald A Zakrowski officer: Chief Accounting Officer LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Alonzo Weems officer: SVP, ERM & CECO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Patrik Jonsson officer: SVP and Pres., Lilly Bio-Meds LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Anne E. White officer: SVP & Pres-Lilly Oncology LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Eric Dozier officer: EVP, HR & Diversity LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Jackson P Tai director
Mary Lynne Hedley director C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Marschall S Runge director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Naarden Jacob Van officer: SVP, CEO LoxoONC, Pres LlyONC C/O ELI LILLY & CO, LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Diogo Rau officer: SVP & CIDO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Edgardo Hernandez officer: SVP & Pres., Mfg. Operations LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Kimberly H Johnson director C/O FANNIE MAE, 1100 15TH STREET, NW, WASHINGTON DC 20005
Anat Ashkenazi officer: SVP & CFO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Gabrielle Sulzberger director 450 LEXINGTON AVENUE, FLOOR 13, NEW YORK NY 10017

Eli Lilly and Co (Eli Lilly and Co) Headlines